Bài đăng

Hiển thị các bài đăng có nhãn cancer

Colon, lung cancer: Cardiorespiratory fitness may lower risk

Hình ảnh
Share on Pinterest Researchers have found a link between cardiorespiratory fitness and the risk of certain cancers in men. Alexandra Bergam/Stocksy Moderate and high cardiorespiratory fitness is associated with a lower incidence of certain cancers in men, according to a new Swedish study . The study’s authors found a solid association between this type of fitness and a reduction in mortality for colon and prostate cancer, as well as for lung cancer for people over 60. The positive link between cardiorespiratory fitness and young non-smokers was especially significant. A large new study from Sweden finds that cardiorespiratory fitness is associated with a lower risk of dying from colon, lung, and prostate cancer. Cardiorespiratory fitness , or CRF, refers to the ability to perform whole-body, large muscle exercise of moderate- to high-intensity for extended periods of time. Such activities involve one’s cardiovascular and respiratory systems. The study’s findings are a bit complicated i...

FDA alerts health care professionals and oncology clinical investigators about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer

[ 9/08/2020 ] FDA is alerting health care professionals, oncology clinical investigators, and patients that a clinical trial studying the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) showed the drug combination did not work to treat the disease.   Atezolizumab in combination with paclitaxel is not approved for use in breast cancer. However, atezolizumab in combination with paclitaxel protein-bound (Abraxane)—a different combination therapy—is currently approved for the treatment of adult patients with mTNBC whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test. Continued approval of atezolizuma...